<?xml version="1.0" encoding="UTF-8"?>
<table-wrap position="float" id="t0020">
 <label>Table 7.3</label>
 <caption>
  <p>In vitro and in vivo PK, tolerability, and efficacy studies of antivirals against biothreat viral agents.</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th valign="bottom" align="left">Therapeutic</th>
    <th valign="bottom" align="left">Target</th>
    <th valign="bottom" align="left">Efficacy data</th>
    <th valign="bottom" align="left">PK and tolerability</th>
    <th valign="bottom" align="left">Additional information and comments</th>
    <th valign="bottom" align="left">References</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td colspan="6" align="left">EBOV</td>
   </tr>
   <tr>
    <td rowspan="4" align="left">BCX4430</td>
    <td rowspan="4" align="left">Viral polymerase</td>
    <td align="left">In vitro—Kikwit EC
     <sub>50</sub>: 11.8 μM; EC
     <sub>90</sub>: 25.4 μM
    </td>
    <td rowspan="4" align="left">Well tolerated in all efficacy studies. Very short plasma half-life in mouse and NHP (
     <italic>T</italic>
     <sub>1/2</sub> = 2–10 min). Mouse, 150 mg/kg, IM: liver, 
     <italic>C</italic>
     <sub>max</sub> (triphosphate) = 65 μM, 
     <italic>T</italic>
     <sub>max</sub> = 8 h, 
     <italic>T</italic>
     <sub>1/2</sub> = 4.3 h. Conversion to triphosphate in hepatocytes: mouse&gt;human ∼NHP
    </td>
    <td rowspan="4" align="left">BCX4430-TP levels in mouse liver at 150 mg/kg IM are ∼2.5× above EC
     <sub>90</sub> value. Distribution into other tissues/cells not reported
    </td>
    <td rowspan="4" align="left">
     <xref rid="bib0450" ref-type="bibr">[89]</xref>, 
     <xref rid="bib0455" ref-type="bibr">[90]</xref>, 
     <xref rid="bib0460" ref-type="bibr">[91]</xref>
    </td>
   </tr>
   <tr>
    <td align="left">In vivo—mice: 150 mg/kg BID PO; 90% survival; 150 mg/kg BID IM; 100% survival</td>
   </tr>
   <tr>
    <td align="left">NHP: 25 mg/kg BID D0–14; 100% survival; 100 mg/kg BID IM D2, then 25 mg/kg BID D3–11, 100% survival (67% with same regimen starting on D3)</td>
   </tr>
   <tr>
    <td align="left">In vivo—HP: 10 mg/kg iv D3–15; 100% protection</td>
   </tr>
   <tr>
    <td align="left">Favipiravir (T-705)</td>
    <td align="left">Viral polymerase</td>
    <td align="left">In vitro—IC
     <sub>50</sub>: 67 μM; EC
     <sub>50</sub> = 281 μM (Kikwit), 223 μM (Makona), 51 μM (Marburg Ci67)
    </td>
    <td align="left">Favipirivir-ribose-TP concentrations were measured in various cell lines and mouse tissues</td>
    <td align="left">Intracellular ribosylation required prior to triphosphorylation to active drug</td>
    <td align="left">
     <xref rid="bib0465" ref-type="bibr">[92]</xref>, 
     <xref rid="bib0470" ref-type="bibr">[93]</xref>, 
     <xref rid="bib0475" ref-type="bibr">[94]</xref>, 
     <xref rid="bib0480" ref-type="bibr">[95]</xref>, 
     <xref rid="bib0485" ref-type="bibr">[96]</xref>
    </td>
   </tr>
   <tr>
    <td/>
    <td/>
    <td align="left">In vivo—mice: 100% survival at 300 mg/kg D0–7 against aerosol challenge; 100% survival at 300 mg/kg beginning D6 following intranasal challenge 
     <xref rid="bib0465" ref-type="bibr">[92]</xref>; 90% survival observed at 8 mg/kg 
     <xref rid="bib0210" ref-type="bibr">[41]</xref>. NHP: Marburg (Angola), 83% survival at 250 mg/kg, iv loading dose + 150 mg/kg, BID for 13 days
    </td>
    <td align="left">Biodistribution in mice assessed by PET imaging. Plasma favipirivir-ribose-TP levels in NHPs following 200 mg/kg, iv loading dose and 150 mg/kg, iv, BID daily dose were 4–34 μM—below the MARV EC
     <sub>50</sub> of 51 μM
    </td>
    <td/>
    <td/>
   </tr>
   <tr>
    <td align="left">GS-5734</td>
    <td align="left">Viral polymerase</td>
    <td align="left">In vitro—replication: EC
     <sub>50</sub>: 0.086–0.14 μM
    </td>
    <td align="left">NHP PK 10 mg/kg, iv, short plasma 
     <italic>T</italic>
     <sub>1/2</sub> of GS-5734, rapid intracellular conversion to triphosphate with persistent levels &gt;EBOV EC
     <sub>50</sub> for 24 h, intracellular triphosphate 
     <italic>T</italic>
     <sub>1/2</sub> = 14 h
    </td>
    <td align="left">NHP tissue distribution plasma∼testes&gt; eye&gt;brain</td>
    <td align="left">
     <xref rid="bib0490" ref-type="bibr">[97]</xref>
    </td>
   </tr>
   <tr>
    <td rowspan="2" align="left">Clomiphene</td>
    <td rowspan="2" align="left">CAD, entry inhibitor</td>
    <td align="left">In vitro—IC
     <sub>50</sub>: 11.1 μM (Kikwit)
     <break/>IC
     <sub>50</sub>: 3.83 μM (Mayinga)
    </td>
    <td rowspan="2" align="left">Mouse PK unavailable. Human PK 50 mg QD: 
     <italic>C</italic>
     <sub>max</sub> = 37 nM. Protein binding not reported, but likely high due to structure similarity to toremifene
    </td>
    <td rowspan="2" align="left">Estrogen receptor modulator, human-free drug exposure = Ebola EC
     <sub>50</sub>
    </td>
    <td rowspan="2" align="left">
     <xref rid="bib0495" ref-type="bibr">[98]</xref>, 
     <xref rid="bib0500" ref-type="bibr">[99]</xref>
    </td>
   </tr>
   <tr>
    <td align="left">In vivo—Mice: 60 mg/kg IP QD on days 0, 1, 3, 5, 7, and 9; 90% survival</td>
   </tr>
   <tr>
    <td rowspan="2" align="left">Bepridil</td>
    <td rowspan="2" align="left">CAD, entry inhibitor</td>
    <td align="left">In vitro—IC
     <sub>50</sub>: 5.08 μM (Vero)
     <break/>IC
     <sub>50</sub>: 3.21 μM (HepG2)
    </td>
    <td rowspan="2" align="left">Mouse PK unavailable; human PK 300 mg PO QD: 
     <italic>C</italic>
     <sub>max</sub> ∼ 6.3 μM, PPB &gt; 99%
    </td>
    <td rowspan="2" align="left">Calcium channel blocker, human-free drug plasma exposure = Ebola EC
     <sub>50</sub>, QT prolongation issues
    </td>
    <td align="left">
     <xref rid="bib0505" ref-type="bibr">[100]</xref>
    </td>
   </tr>
   <tr>
    <td align="left">In vivo—Mice: 12 mg/kg; 100% survival</td>
    <td/>
   </tr>
   <tr>
    <td align="left">Brincidofovir</td>
    <td align="left">Unknown</td>
    <td align="left">In vitro—EC
     <sub>50</sub>: 120 nm–1.3 μM
    </td>
    <td/>
    <td align="left">Interferes with viral DNA replication</td>
    <td rowspan="2" align="left">
     <xref rid="bib0510" ref-type="bibr">[101]</xref>, 
     <xref rid="bib0515" ref-type="bibr">[102]</xref>
    </td>
   </tr>
   <tr>
    <td/>
    <td/>
    <td align="left">In vivo—no preclinical efficacy reported</td>
    <td/>
    <td/>
   </tr>
   <tr>
    <td rowspan="3" align="left">Type I IFN</td>
    <td rowspan="3" align="left">NA</td>
    <td align="left">In vitro—IFN-α IC
     <sub>50</sub>: 0.038 μM
     <break/>IFN-β IC
     <sub>50</sub>: 0.016 μM
    </td>
    <td rowspan="3"/>
    <td rowspan="3"/>
    <td rowspan="3" align="left">
     <xref rid="bib0520" ref-type="bibr">[103]</xref>, 
     <xref rid="bib0525" ref-type="bibr">[104]</xref>, 
     <xref rid="bib0530" ref-type="bibr">[105]</xref>
    </td>
   </tr>
   <tr>
    <td align="left">In vivo—IFN-α2b in NHP: delayed time to death</td>
   </tr>
   <tr>
    <td align="left">IFN-β in NHP: 10.5 μg/kg at 18 h and days 1, 3, 5, 7, and 9; delayed time to death</td>
   </tr>
   <tr>
    <td rowspan="2" align="left">TKM-100802, TKM-130803</td>
    <td rowspan="2" align="left">L, VP35, VP24</td>
    <td align="left">In vitro—not available</td>
    <td rowspan="2" align="left"/>
    <td rowspan="2" align="left">Lipid nanoparticle formulation of siRNAs</td>
    <td rowspan="2" align="left">
     <xref rid="bib0535" ref-type="bibr">[106]</xref>, 
     <xref rid="bib0540" ref-type="bibr">[107]</xref>
    </td>
   </tr>
   <tr>
    <td align="left">In vivo—NHP: 100% survival against Kikwit and Makona</td>
   </tr>
   <tr>
    <td rowspan="2" align="left">AVI-6002</td>
    <td rowspan="2" align="left">VP24/VP35</td>
    <td align="left">In vitro—not available</td>
    <td rowspan="2"/>
    <td align="left">Combination of AVI-7537 and AVI-7539 phosphorodiamidate morpholino oligomers</td>
    <td rowspan="2" align="left">
     <xref rid="bib0545" ref-type="bibr">[108]</xref>, 
     <xref rid="bib0550" ref-type="bibr">[109]</xref>, 
     <xref rid="bib0555" ref-type="bibr">[110]</xref>
    </td>
   </tr>
   <tr>
    <td align="left">In vivo—NHP: up to 63% survival at 40 mg/kg</td>
    <td/>
   </tr>
   <tr>
    <td rowspan="2" align="left">AVI-7537</td>
    <td rowspan="2" align="left">VP24</td>
    <td align="left">In vitro—0.585 μM</td>
    <td rowspan="2"/>
    <td align="left">Phosphorodiamidate morpholino oligomer</td>
    <td rowspan="2" align="left">
     <xref rid="bib0545" ref-type="bibr">[108]</xref>, 
     <xref rid="bib0555" ref-type="bibr">[110]</xref>
    </td>
   </tr>
   <tr>
    <td align="left">In vivo—NHP: 40 mg/kg; 75% survival</td>
    <td/>
   </tr>
   <tr>
    <td colspan="6" align="left">LASV</td>
   </tr>
   <tr>
    <td align="left">Ribavirin</td>
    <td align="left">Viral polymerase</td>
    <td align="left">In vitro—yield reduction assay, Vero cells, IC
     <sub>90</sub> = 2.5 μM, Junin (Romero); 3.6 μM, Junin (Candid#1); plaque assay, Junin (Romero), Vero E6 cells, EC
     <sub>90</sub> = 71 μM
     <break/>In vivo—NHP: 50 mg/kg, s.c. (loading dose) followed by 10 mg/kg, s.c. every 8 h through day 18; 4 animals dosed immediately after infection, 4 dosed 5 days post infection; 8/8 survived versus 4/10 in control group
    </td>
    <td align="left">Ribavirin is intracellularly triphosphorylated to the active drug. In humans, plasma concentrations of ribavirin have been correlated to virological response</td>
    <td align="left">Nucleoside drug; FDA approved for RSV and HCV</td>
    <td align="left">
     <xref rid="bib0560" ref-type="bibr">[111]</xref>, 
     <xref rid="bib0565" ref-type="bibr">[112]</xref>, 
     <xref rid="bib0570" ref-type="bibr">[113]</xref>, 
     <xref rid="bib0575" ref-type="bibr">[114]</xref>
    </td>
   </tr>
   <tr>
    <td align="left">Stampidine</td>
    <td align="left">Viral polymerase</td>
    <td align="left">In vivo—CBA mice, cerebral injection of Lassa (Josiah): 50 mg/kg, i.p., dosed daily for 6 days starting 24 h prior to infection, 90% survival compared to 25% vehicle survival</td>
    <td align="left">Rapidly converted to its active form (Ala-MP) within 5 min in plasma. No notable toxicity after daily i.p. or p.o. admin for 8 weeks (cumulative dose 6.4 g/kg)</td>
    <td align="left">Nucleoside monophosphate prodrug; reverse transcriptase inhibitor against HIV</td>
    <td align="left">
     <xref rid="bib0580" ref-type="bibr">[115]</xref>
    </td>
   </tr>
   <tr>
    <td align="left">Zidampidine</td>
    <td align="left">Viral polymerase</td>
    <td align="left">In vivo—CBA mice, cerebral injection of Lassa (Josiah): 25 mg/kg, i.p., dosed daily for 6 days starting 24 h prior to infection, 100% survival compared to 28% vehicle survival</td>
    <td align="left">Rapidly converted to its metabolites Ala-AZT-MP and AZT following iv injection. Nontoxic to mice up to 250 mg/kg</td>
    <td align="left">Nucleoside monophosphate prodrug of zidovudine (AZT)</td>
    <td align="left">
     <xref rid="bib0585" ref-type="bibr">[116]</xref>
    </td>
   </tr>
   <tr>
    <td colspan="6" align="left">LASV, JUNV</td>
   </tr>
   <tr>
    <td rowspan="2" align="left">LHF-535</td>
    <td rowspan="2" align="left">Entry inhibitor</td>
    <td align="left">In vitro—yield reduction assay, Vero cells, IC
     <sub>90</sub> = 9.3 nM, Junin (Romero); 3 μM, Junin (Candid#1)
    </td>
    <td rowspan="2" align="left">Not available</td>
    <td rowspan="2" align="left">Small molecule</td>
    <td rowspan="2" align="left">
     <xref rid="bib0560" ref-type="bibr">[111]</xref>
    </td>
   </tr>
   <tr>
    <td align="left">In vivo—Tacaribe virus, AG129 mice: 100% survival, 10 mg/kg/day, p.o. for 14 days starting 30 min prior to infect.; 60%–90% survival when dosed 24–72 h post infection</td>
   </tr>
   <tr>
    <td rowspan="2" align="left">Favipiravir (T-705)</td>
    <td rowspan="2" align="left">Viral polymerase</td>
    <td align="left">In vitro—plaque assay, Junin (Romero), Vero E6 cells, EC
     <sub>90</sub> = 21 μM
    </td>
    <td rowspan="2" align="left">PK, biodistribution, and favipiravir-ribose-triphosphate levels discussed above</td>
    <td rowspan="2" align="left">Intracellular ribosylation required prior to triphosphorylation to active drug</td>
    <td rowspan="2" align="left">
     <xref rid="bib0470" ref-type="bibr">[93]</xref>, 
     <xref rid="bib0475" ref-type="bibr">[94]</xref>, 
     <xref rid="bib0480" ref-type="bibr">[95]</xref>, 
     <xref rid="bib0565" ref-type="bibr">[112]</xref>, 
     <xref rid="bib0590" ref-type="bibr">[117]</xref>
    </td>
   </tr>
   <tr>
    <td align="left">In vivo—LASV (Josiah), cynomolgus macaques: 4/4 survival versus 0/4 placebo, 300 mg/kg, iv on day 4 followed by 300 mg/kg, s.c., qd days 5–17</td>
   </tr>
   <tr>
    <td colspan="6" align="left">VEEV</td>
   </tr>
   <tr>
    <td align="left">β-
     <sc>d</sc>-N4-hydroxycytidine
    </td>
    <td align="left">Viral polymerase</td>
    <td align="left">In vitro—VEEV EC
     <sub>50</sub> = 1.2 μM (HeLa), 1.3 μM (Vero); 99% inhibition at 10 μM (astrocytes)
    </td>
    <td align="left">Rat brain nucleoside TP levels after single 50 mg/kg, p.o. dose are near VEEV EC
     <sub>50</sub> values (526 ng/g at 2.5 h, 135 ng/g at 24 h)
    </td>
    <td align="left">Broad-spectrum antiviral (EEEV, WEEV, VEEV, and numerous nonbiothreat viruses such as CHIKV, MERV, influenza, and RSV)</td>
    <td align="left">
     <xref rid="bib0595" ref-type="bibr">[118]</xref>
    </td>
   </tr>
   <tr>
    <td rowspan="2" align="left">ML366</td>
    <td rowspan="2" align="left">nsP2, nsP4</td>
    <td align="left">In vitro—EC
     <sub>50</sub> (VEEV TC-83) = 32 nM (Vero)
    </td>
    <td rowspan="2" align="left">Mouse brain drug levels (single 10 mg/kg, i.p.) at 2 h post dose were 0.35 μM</td>
    <td rowspan="2"/>
    <td rowspan="2" align="left">
     <xref rid="bib0600" ref-type="bibr">[119]</xref>, 
     <xref rid="bib0605" ref-type="bibr">[120]</xref>
    </td>
   </tr>
   <tr>
    <td align="left">In vivo—VEEV TrD (s.c. injection), BALB/c mice, 12.5 mg/kg, i.p. every 12 h for 8 days starting 2 h preinfection, 100% survival</td>
   </tr>
   <tr>
    <td rowspan="2" align="left">BDGR-4</td>
    <td rowspan="2" align="left">nsP2, nsP4</td>
    <td align="left">In vitro—EC
     <sub>50</sub> (Vero) = 47 nM (VEEV TC-83), 150 nM (EEEV), 102 nM (WEEV)
    </td>
    <td rowspan="2"/>
    <td rowspan="2" align="left">Close-in analog to ML366</td>
    <td rowspan="2" align="left">
     <xref rid="bib0600" ref-type="bibr">[119]</xref>
    </td>
   </tr>
   <tr>
    <td align="left">In vivo—VEEV TrD (s.c. injection), BALB/c mice, 12.5 mg/kg, i.p. every 12 h for 8 days starting 24 h post infection, 100% survival (90% starting 48 h post infection). EEEV (s.c. injection), C57BL/6 mice, 25 mg/kg, i.p. every 12 h for 8 days starting 2 h preinfection, 90% survival</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <fn>
   <p>
    <italic>EBOV</italic>, Ebola virus; 
    <italic>HCV</italic>, Hepatitis C virus; 
    <italic>IFN</italic>, Interferon; 
    <italic>JUNV</italic>, Junin virus; 
    <italic>LASV</italic>, 
    <italic>Lassa virus</italic>; 
    <italic>NHP</italic>, nonhuman primate; 
    <italic>NHP</italic>, nonhuman primate; 
    <italic>PPB</italic>, plasma protein binding; 
    <italic>PK</italic>, pharmacokinetic; 
    <italic>PET</italic>, positron emission tomography; 
    <italic>RSV</italic>, respiratory syncytial virus; 
    <italic>TP</italic>, triphosphate; 
    <italic>VEEV</italic>, venezuelan equine encephalitis virus.
   </p>
  </fn>
 </table-wrap-foot>
</table-wrap>
